Patents by Inventor Stephen Hoge

Stephen Hoge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240024422
    Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
    Type: Application
    Filed: February 6, 2023
    Publication date: January 25, 2024
    Inventors: Joshua FREDERICK, Susannah HEWITT, Ailin BAI, Stephen HOGE, Vladimir PRESNYAK, Iain MCFADYEN, Kerry BENENATO, Ellalahewage Sathyajith KUMARASINGHE
  • Patent number: 11801227
    Abstract: The invention relates to mRNA therapy for the treatment of cystic fibrosis. mRNAs for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR), isoforms thereof, functional fragments thereof, and fusion proteins comprising CFTR. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of CFTR expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient CFTR activity in subjects.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: October 31, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Kerry Benenato, Stephen Hoge, Iain McFadyen, Vladimir Presnyak, Paolo Martini, Ellalahewage Sathyajith Kumarasinghe
  • Publication number: 20230338410
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Application
    Filed: February 13, 2023
    Publication date: October 26, 2023
    Inventors: Stephen HOGE, Tirtha CHAKRABORTY, Gilles BESIN, Ruchi JAIN
  • Publication number: 20230330260
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins.
    Type: Application
    Filed: June 28, 2023
    Publication date: October 19, 2023
    Applicant: ModemaTX, Inc.
    Inventors: Stephen Hoge, Jeseph Schariter, Charles Bowerman, Michael H. Smith, Yan Xia
  • Patent number: 11786607
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 17, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, Joseph Schariter, Charles Bowerman, Michael H. Smith, Yan Xia
  • Publication number: 20230285538
    Abstract: High quality vaccines are identified and formulated based on a threshold differential T-cell activation potential. The vaccines are mRNA vaccines formulated in a carrier, wherein the mRNA encodes an antigen.
    Type: Application
    Filed: May 16, 2023
    Publication date: September 14, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Stephen Hoge, Giuseppe Giaramella
  • Publication number: 20230270685
    Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.
    Type: Application
    Filed: November 18, 2022
    Publication date: August 31, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Paolo Martini, Vladimir Presnyak, Kerry Benenato, Stephen Hoge, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe
  • Publication number: 20230233475
    Abstract: This disclosure relates to ionizable lipid-based lipid nanoparticles for delivery of mRNA encoding glucose-6-phosphatase. Lipid nanoparticle/mRNA therapies of the invention increase and/or restore deficient levels of glucose-6-phosphatase expression and activity in subjects and are useful for the treatment of glycogen storage disease type 1a (GSD-Ia). Lipid nanoparticle/mRNA therapies of the invention increase glucose production and reduce the abnormal accumulation of glycogen and glucose-6-phosphate associated with GSD-Ia.
    Type: Application
    Filed: June 1, 2021
    Publication date: July 27, 2023
    Inventors: Kerry Benenato, Kristine Burke, Jingsong Cao, Paloma Hoban Giangrande, Edward J. Hennessy, Stephen Hoge, Jaclyn Milton, Staci Sabnis, Timothy Salerno, Matthew Theisen
  • Publication number: 20230146324
    Abstract: The present disclosure provides multiparametric codon optimization methods to improve at least a property in a candidate nucleic acid sequence, for example the translation efficacy of a therapeutic mRNA.
    Type: Application
    Filed: February 28, 2022
    Publication date: May 11, 2023
    Inventors: John van Wicheren REYNDERS, III, Tirtha CHAKRABORTY, Stephen HOGE, Iain James MCFADYEN
  • Publication number: 20230112986
    Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).
    Type: Application
    Filed: July 21, 2022
    Publication date: April 13, 2023
    Applicants: ModernaTX, Inc., Fundacion Para La Investigacion Medica Aplicada
    Inventors: Paolo MARTINI, Stephen HOGE, Kerry BENENATO, Vladimir PRESNVAK, Lei JIANG, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Antonio FONTANELLAS ROMA, Pedro BERRAONDO LOPEZ, Matias Antonio AVILA ZARAGOZA, Lin Tung GUEY, Staci SABNIS
  • Patent number: 11596609
    Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36? (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: March 7, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Joshua Frederick, Ailin Bai, Vladimir Presnyak, Stephen Hoge, Kerry Benenato, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Susannah Hewitt
  • Patent number: 11590157
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: February 28, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
  • Publication number: 20230041964
    Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36? (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
    Type: Application
    Filed: May 27, 2022
    Publication date: February 9, 2023
    Inventors: Joshua FREDERICK, Ailin BAI, Vladimir PRESNYAK, Stephen HOGE, Kerry BENENATO, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Susannah HEWITT
  • Patent number: 11571463
    Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: February 7, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Joshua Frederick, Susannah Hewitt, Ailin Bai, Stephen Hoge, Vladimir Presnyak, Iain James McFadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
  • Publication number: 20230026381
    Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36? (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
    Type: Application
    Filed: September 7, 2022
    Publication date: January 26, 2023
    Inventors: Joshua FREDERICK, Ailin BAI, Vladimir PRESNYAK, Stephen HOGE, Kerry BENENATO, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Susannah HEWITT
  • Patent number: 11504337
    Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: November 22, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Paolo Martini, Vladimir Presnyak, Kerry Benenato, Stephen Hoge, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe
  • Publication number: 20220296517
    Abstract: The disclosure features target cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to target cells, in particular liver cells and/or splenic cells. The LNPs comprise an effective amount of a target cell delivery potentiating lipid such that delivery of an agent by a target cell target cell delivery LNP is enhanced as compared to an LNP lacking the target cell delivery potentiating agent. Methods of using the target cell target cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, and for modulating target cell activity are also disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: September 22, 2022
    Inventors: Kerry Benenato, Staci Sabnis, Edward Hennessy, Kristine Burke, Matthew Theisen, Jaclyn Milton, Timothy Salerno, Stephen Hoge
  • Publication number: 20220265857
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Application
    Filed: January 25, 2022
    Publication date: August 25, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Publication number: 20220265774
    Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 25, 2022
    Inventors: Joshua FREDERICK, Susannah HEWITT, Ailin BAI, Stephen HOGE, Vladimir PRESNYAK, Iain James MCFADYEN, Kerry BENENATO, Ellalahewage Sathyajith KUMARASINGHE
  • Patent number: 11311602
    Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: April 26, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Joshua Frederick, Susannah Hewitt, Ailin Bai, Stephen Hoge, Vladimir Presnyak, Iain McFadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe